Supernus Pharmaceuticals (SUPN) Debt to Equity (2020 - 2025)
Historic Debt to Equity for Supernus Pharmaceuticals (SUPN) over the last 9 years, with Q3 2025 value amounting to $0.01.
- Supernus Pharmaceuticals' Debt to Equity fell 7685.77% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.01, marking a year-over-year decrease of 7685.77%. This contributed to the annual value of $0.05 for FY2024, which is 1910.98% down from last year.
- As of Q3 2025, Supernus Pharmaceuticals' Debt to Equity stood at $0.01, which was down 7685.77% from $0.03 recorded in Q1 2025.
- Supernus Pharmaceuticals' Debt to Equity's 5-year high stood at $0.52 during Q4 2021, with a 5-year trough of $0.01 in Q3 2025.
- Its 5-year average for Debt to Equity is $0.12, with a median of $0.05 in 2024.
- Over the last 5 years, Supernus Pharmaceuticals' Debt to Equity had its largest YoY gain of 151863.38% in 2022, and its largest YoY loss of 9541.53% in 2022.
- Supernus Pharmaceuticals' Debt to Equity (Quarter) stood at $0.52 in 2021, then crashed by 95.42% to $0.02 in 2022, then skyrocketed by 137.1% to $0.06 in 2023, then decreased by 19.11% to $0.05 in 2024, then crashed by 76.58% to $0.01 in 2025.
- Its Debt to Equity stands at $0.01 for Q3 2025, versus $0.03 for Q1 2025 and $0.05 for Q4 2024.